| [1] |
REN XF, ZHUGE YZ, CHEN SY, et al. Gynura segetum-related hepatic sinusoidai obstruction syndrome: a national multicenter clinical study[J]. Chin J Dig, 2017, 37(8): 523-529. DOI: 10.3760/cma.j.issn.0254-1432.2017.08.004. |
| [2] |
LIU SS, ZHOU XD. Study on gynura segetum-induced hepatic sinusoidal obstruction syndrome[J]. J Clin Intern Med, 2020, 37(4): 256-259. DOI: 10.3969/j.issn.1001-9057. 2020.04.004.
刘少松, 周晓东. 吡咯烷生物碱诱导肝窦阻塞综合征的研究进展[J]. 临床内科杂志, 2020, 37(4): 256-259. DOI: 10.3969/j.issn.1001-9057. 2020.04.004.
|
| [3] |
Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing)[J]. J Clin Hepatol, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003. |
| [4] |
XIAO J, TU J, ZHANG H, et al. Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt[J]. Hepatol Int, 2021, 15(3): 720-729. DOI: 10.1007/s12072-020-10126-x. |
| [5] |
WANG JY, GAO H. Tusanqi and hepatic sinusoidal obstruction syndrome[J]. J Dig Dis, 2014, 15(3): 105-107. DOI: 10.1111/1751-2980.12112. |
| [6] |
WANG LL, SUN J. Advances in diagnosis and treatment of hepatic sinus obstruction syndrome caused by pyrrole alkaloids[J]. Int J Dig Dis, 2020, 40(2): 96-99. DOI: 10.3969/j.issn. 1673-534X.2020.02.008.
王露露, 孙璟. 吡咯生物碱导致的肝窦阻塞综合征的诊治进展[J]. 国际消化病杂志, 2020, 40(2): 96-99. DOI: 10.3969/j.issn. 1673-534X.2020.02.008.
|
| [7] |
LIU ZL, FAN ZP, GOU YS. Clinical features, pathogenesis, and diagnosis and treatment of different types of hepatic sinusoidal obstruction syndrome[J]. J Clin Hepatol, 2019, 35(1): 208-212. DOI: 10.3969/j.issn.1001-5256.2019.01.046. |
| [8] |
DIGNAN FL, WYNN RF, HADZIC N, et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation[J]. Br J Haematol, 2013, 163(4): 444-457. DOI: 10.1111/bjh.12558. |
| [9] |
MOHTY M, MALARD F, ABECASSIS M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)[J]. Bone Marrow Transplant, 2015, 50(6): 781-789. DOI: 10.1038/bmt.2015.52. |
| [10] |
LI SY, WANG Y. Progress in the pathogenesis, clinical diagnosis and treatment of hepatic sinus obstruction syndrome induced by Tuanqi[J]. Chin Hepatol, 2018, 23(6): 540-542. DOI: 10.3969/j.issn.1008-1704.2018.06.027. |
| [11] |
LIU Z, JI SL, WANG FS. Research progress of the pharmacological effects and clinical applications of low molecular weight heparins[J]. Pharm Biotech, 2014, 21(6): 573-578. DOI: 10.19526/j.cnki.1005-8915.2014.06.020. |
| [12] |
Branch of Gastrointestinal Diseases, China Association of Chinese Medicine. Expert consensus on TCM diagnosis and treatment of ascites due to cirrhosis (2017)[J]. J Clin Hepatol, 2017, 33(9): 1621-1626. DOI: 10.3969/j.issn.1001-5256.2017.09.002. |
| [13] |
JIANG MJ, SONG LS, XIN GJ, et al. Low-molecular-weight heparin sodium for the treatment of hepatic sinusoidal obstruction syndrome: A case report[J]. J Clin Hepatol, 2019, 35(7): 1594-1595. DOI: 10.3969/j.issn.1001-5256.2019.07.035. |
DownLoad:
